April 2026 in Peptides: The Month That Reset the Industry

April 2026 was the most consequential month for peptide therapeutics in years. The FDA approved Foundayo, the first oral small-molecule GLP-1, in 50 days under the National Priority Voucher pilot. Twelve research peptides — BPC-157, TB-500, KPV, GHK-Cu, MOTs-C, and others — came off the FDA's Category 2 restricted list on April 22, ahead of a July 23–24 PCAC meeting. Boehringer and Zealand reported positive Phase 3 SYNCHRONIZE-1 data for survodutide. Lilly closed the month with a $19.8 billion Q1 print (Mounjaro +125%, Zepbound +80%) and a fresh Phase 3 retatrutide readout in type-2 diabetes. The FDA proposed striking semaglutide, tirzepatide, and liraglutide from the 503B bulks list on the same day, effectively closing the door on large-scale compounding. AACR 2026 in San Diego loaded the oncology field with peptide-drug conjugate, bicyclic peptide, and peptide-vaccine readouts. And the consumer-facing peptide story moved fully into the mainstream — STAT, Scientific American, NPR, ABC News affiliates, the Washington Post, the AMA, and AJMC all ran significant pieces.

Eli Lilly's orforglipron — branded Foundayo — won FDA approval for chronic weight management on April 1, 2026, becoming the fifth product cleared under the Commissioner's National Priority Voucher pilot and the fastest NME approval since 2002 (50 days from filing). It is technically a small molecule, not a peptide, but it acts on the GLP-1 receptor and competes directly with oral semaglutide. Unlike Rybelsus and the Wegovy pill, Foundayo has no food or water restrictions.

IQVIA's Foundayo launch tracker showed 1,390 prescriptions in week one, 3,707 in week two, and 5,612 in week three — climbing, but well behind the Wegovy pill, which hit roughly 113,000 weekly prescriptions by early May. On the April 30 Q1 call, Lilly said about 20,000 patients are now on Foundayo, with more than 8,000 prescribers writing it (one-third of them writing an oral GLP-1 for the first time) and commercial access at two of the three largest US PBMs effective mid-May. Hims & Hers added Foundayo to its platform via LillyDirect on April 23.

Two regulatory moves reshaped the compounding economy. On April 22, twelve peptides — BPC-157, TB-500, KPV, MOTs-C, GHK-Cu (injectable), Cathelicidin LL-37, DiHexa, DSIP, Epitalon, PEG-MGF, Melanotan II, and Semax — formally exited the FDA's Category 2 restricted list. Category 2 removal does not authorize compounding on its own, but it clears the procedural runway for the July 23–24 PCAC meeting that will recommend whether seven of those peptides (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) should join the 503A bulks list. Five more — Cathelicidin, DiHexa, PEG-MGF, GHK-Cu, Melanotan II — are slated for a follow-up panel by February 2027.

On April 30, the FDA went the other direction on GLP-1s. The agency proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'no clinical need' now that branded supply has stabilized. Comments are open through June 29. The Partnership for Safe Medicines applauded the move; Orrick's May client memo translated the implications for telehealth platforms and weight-loss clinics. A University of Colorado secret-shopper study earlier in the month found 69 of 74 medspas surveyed still selling compounded semaglutide despite the resolved shortage.

Lilly's Q1 2026 print on April 30 set the financial frame for the year. Worldwide revenue: $19.8 billion (+56% YoY), driven by Mounjaro at $8.66B globally (+125%) and Zepbound at $4.16B in US sales (+80%). Reported EPS jumped 170% to $8.26. Lilly raised 2026 revenue guidance by $2 billion at each end to $82–85B, lifted non-GAAP EPS guidance to $35.50–$37.00, and the stock rose 6.11% on May 1.

The Q1 call also disclosed positive topline results from TRANSCEND T2D1, the first Phase 3 trial of the triple GLP-1/GIP/glucagon agonist retatrutide in type-2 diabetes: A1c down 1.7 to 2.0 percentage points and 25 to 37 lb mean weight loss versus placebo. TRIUMPH-4 results in obesity with knee osteoarthritis (28.7% mean weight loss, 75.8% pain reduction) had landed earlier. Seven additional retatrutide Phase 3 readouts are due in 2026. Lilly also closed the Orna, Centessa, Colonia, and Ajax acquisitions in the quarter, completed the $7B Kelonia Therapeutics in-vivo CAR-T deal on April 29, and signed a $2.25B research collaboration with Profluent for AI-designed site-specific recombinases on April 28.

Novo Nordisk spent April defending semaglutide. The Wegovy pill — oral semaglutide 25 mg cleared for obesity in late 2025 — kept building US retail volume and reached roughly 113,000 weekly prescriptions per IQVIA by early May. PIONEER TEENS Phase 3a posted superior HbA1c reduction for oral semaglutide in pediatric type-2 diabetes (April 23), positioning the molecule as the first oral GLP-1 with potential pediatric approval. The Hims & Hers collaboration added branded Wegovy injections and the pill to that platform.

The May 1 move closed the loop. Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies starting May 4 — leaning on Ozempic's brand recognition and using a reformulated, smaller tablet with improved absorption and bioavailability. WW Med+ and GoodRx announced parallel access channels the same day. Insured patients can pay as little as $25 for up to a 3-month supply; self-pay tiers run $149–$299 per month by strength. Novo's Q1 print is May 6.

AACR 2026 (April 17–22, San Diego) cemented peptide oncology as a frontline modality. Bicycle Therapeutics led with nuzefatide pevedotin (BT5528), a bicyclic peptide-drug conjugate, hitting 40% ORR in checkpoint-refractory urothelial cancer; the company also presented EphA2 PET imaging data and a gallium-68 first-in-human readout in pancreatic cancer at the meeting's close. Circle Pharma's macrocyclic peptide CID-078 took a Clinical Trials Plenary slot with the first Phase 1 activity data. Greenwich LifeSciences' FLAMINGO-01 GP2 vaccine drove a 4× delayed-type-hypersensitivity response in open-label data. BriaCell's Bria-IMT preserved quality of life in heavily pretreated breast cancer. Perspective Therapeutics' alpha-emitter PRRT hit 43% ORR in neuroendocrine tumors. Avacta's AVA6103 peptide-drug conjugate showed 3× tumor selectivity vs. Enhertu in preclinical work. Evaxion's EVX-01 personalized peptide vaccine reached 75% ORR at two years in metastatic melanoma. Lirum's LX-101 IGF-1R-targeted peptide payload conjugate showed antitumor activity in Ewing sarcoma. ApexOnco's coverage flagged conjugates as the AACR 2026 spotlight modality.

The ESCMID Global 2026 meeting opened in Munich on April 18 with 18,000 attendees and AMR squarely in the spotlight. Fedora Pharmaceuticals presented FPI-2119, a lactivicin-class antibiotic with potent bactericidal activity. Longhorn Vaccines' DRG5-BD11 bispecific IgM targeted bacterial peptidoglycan. The BARNARDS II study reported that WHO first-line antibiotics cover only 1 in 4 neonatal sepsis cases — a sobering AMR data point.

The larger story was the AI-designed antimicrobial peptide (AMP) wave. Houston Methodist's CAMPER framework, published in Nature Communications, identified WP-CAMPER1 — a 12-mer that kills MRSA at 4 µg/mL. A separate Nature Communications few-shot AI pipeline designed AMPs effective against carbapenem-resistant Acinetobacter baumannii. Nature Biomedical Engineering published the HMD-AMP protein language model that screened 37 million+ AMP candidates from mammalian microbiomes. The University of Manchester closed the month with a Nature Communications paper describing an alternative enzymatic pathway to penicillin G, V, and ampicillin via standalone ligase plus engineered IPNS — a cleaner biosynthetic route to legacy antibiotics in an AMR landscape where supply economics matter as much as new chemistry.

UTHealth BLMP6 (April 29). Mikhail Kolonin's group published a Molecular Therapy Oncology paper showing that BLMP6, an AI-discovered peptide, selectively binds fibulin-4 on metastatic triple-negative breast cancer cells. A BLMP6-MMAE conjugate suppressed metastasis and improved survival in mouse models.

Stanford PAM-enzyme study. A Genome Medicine paper from a Stanford-led team identified two PAM (peptidyl-glycine alpha-amidating monooxygenase) variants present in roughly 10% of the population that blunt GLP-1 glycemic response — the first in-depth investigation of a 'GLP-1 resistance' phenotype, alongside the recent 23andMe GLP1R/GIPR variant Nature paper.

Mount Sinai liver-detargeted mRNA vaccines (April 29). A Nature Biotechnology paper showed that hepatocytes actively dampen mRNA vaccine immunity; engineering vaccines to avoid hepatocyte expression cut lymphoma tumor burden by more than 50% in mouse models, inverting a longstanding design assumption.

Nature quintuple agonist. The DiMarchi/Tschöp group published a unimolecular GLP-1R/GIPR/PPARα/γ/δ peptide-drug conjugate that combines a GLP-1/GIP co-agonist with the pan-PPAR agonist lanifibranor via a pH-sensitive linker. In obese diabetic mice, the conjugate produced greater weight loss and insulin sensitization than equimolar combinations without the typical PPAR safety signals.

Crinetics Palsonify EU approval (April 27). The European Commission cleared paltusotine, a once-daily oral SST2 nonpeptide agonist, for adult acromegaly across all 27 EU member states — the first non-injectable somatostatin-pathway therapy and Crinetics' first regulatory approval outside the US.

The peptide story moved into mainstream consumer and trade media in April with unusual density. STAT ran two pieces: GLP-1 pioneers DiMarchi and Tschöp proposing to drop GLP-1 as a drug target, then a First Opinion arguing 'RFK Jr.'s peptide push could unleash risky drugs.' Scientific American published 'The Science Behind the Peptide Craze' warning of the gap between hype and evidence. The Washington Post covered the FDA's Category 2 reversal. ABC News affiliates ran a syndicated doctor-warning piece. NPR did the math on 12 million Americans each losing Wegovy and Zepbound coverage in 2026. The Yahoo consumer feature 'Wait, So Are Peptides Legal Now?' translated the Category 2 removal for general audiences. CNN, FOX, and Bloomberg all weighed in.

Trade and clinical outlets followed. The American Journal of Sports Medicine published an injectable-peptide primer for orthopaedic and sports-medicine physicians. The American Medical Association ran 'What Doctors Wish Patients Knew About Injectable Peptides.' AJMC published an oral-peptides FAQ. The FDA Law Blog ran its two-part 'Pep(tide) Rally' for compounders. Holt Law's regulatory deep-dive walked pharmacies through the post-Category-2 status. Eric Topol covered 15 injectable peptides on his Substack. Empower Pharmacy and JustCare Health ran provider-side analyses. The information ecosystem around the post-Category-2 peptide market has now fully formed — and Hims & Hers stock rallied 49% in five sessions on the convergence of peptide reclassification, the Novo Nordisk partnership, and the Lilly LillyDirect deal.

May is dense. Novo Nordisk reports Q1 on May 6. Hims & Hers reports Q1 on May 11. The 33rd European Congress on Obesity (ECO 2026) opens May 12–15 in Istanbul, with Novo presenting 52 abstracts spanning Wegovy 2.4 mg and 7.2 mg, the Wegovy pill, and CagriSema. TIDES USA 2026 — the year's leading peptide and oligonucleotide conference — runs May 11–14 in Boston, featuring Bachem, Gilead, Novo Nordisk, and the post-503B CMC strategy conversation. ASCO 2026 follows May 29–June 2 in Chicago, with Bicycle Therapeutics, BriaCell, BioVaxys, and others on the peptide-oncology slate. Roche's petrelintide+enicepatide Phase 2 combination opens mid-2026; CT-996 oral GLP-1 Phase 2 readouts are guided before year-end. The July 23–24 PCAC meeting on the seven Category 2 peptides remains the regulatory fixed point. The Foundayo IQVIA tracker continues weekly. April 2026 reset the field; May tests whether the new positions hold.